石川 清仁

Medicine & Life Sciences

1. Urinary Tract Infections 100%
2. Cystitis 56%
3. Japan 53%
4. Prostatitis 52%
5. Escherichia coli 48%
6. Fluoroquinolones 46%
7. Infections 42%
8. Clinical Studies 41%
9. Anti-Bacterial Agents 34%
10. Quinolones 31%
11. Urethritis 30%
12. Pyelonephritis 30%
13. Enterococcus faecalis 28%
14. Klebsiella pneumoniae 28%
15. Levofloxacin 25%
16. Prostate 21%
17. Bacteria 21%
18. Pseudomonas aeruginosa 20%
19. Kidney 19%
20. Microbial Sensitivity Tests 18%
21. cefoselis 17%
22. Staphylococcus saprophyticus 16%
23. sitafloxacin 16%
24. Methicillin-Resistant Staphylococcus aureus 16%
25. Guidelines 16%
26. prulifloxacin 16%
27. Anti-Infective Agents 16%
28. Tazobactam Drug Combination Piperacillin 14%
29. Pharmaceutical Preparations 14%
30. biapenem 13%
31. Ciprofloxacin 12%
32. tosufloxacin 11%
33. Drug Therapy 11%
34. Epidemiologic Studies 11%
35. Sexually Transmitted Diseases 11%
36. Therapeutics 11%
37. Azithromycin 11%
38. Neisseria gonorrhoeae 10%
39. Escherichia coli Adhesins 10%
40. Globosides 10%
41. Chlamydia trachomatis 10%
42. Proteus mirabilis 10%
43. Safety 10%
44. Serratia marcescens 9%
45. Imipenem Drug Combination Cilastatin 9%
46. Carbapenems 9%
47. cefozopran 9%
48. Urine 9%
49. Macaca fascicularis 9%
50. Randomized Controlled Trials 9%